{
    "id": "correct_foundationPlace_00020_2",
    "rank": 61,
    "data": {
        "url": "https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine",
        "read_more_link": "",
        "language": "en",
        "title": "Pfizer-BioNTech COVID-19 Vaccine",
        "top_image": "https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png",
        "meta_img": "https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png",
        "images": [
            "https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png",
            "https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg",
            "https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Center for Biologics Evaluation and Research"
        ],
        "publish_date": "2023-12-11T14:48:00",
        "summary": "",
        "meta_description": "Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Authorized For Individuals 6 Months through 11 Years of Age",
        "meta_lang": "en",
        "meta_favicon": "/themes/custom/preview/favicon.ico",
        "meta_site_name": "U.S. Food and Drug Administration",
        "canonical_link": "https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine",
        "text": "On September 11, 2023, the Food and Drug Administration amended the emergency use authorization (EUA) of Pfizer-BioNTech COVID-19 Vaccine to include the 2023-2024 formula. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) includes a monovalent (single) component that corresponds to the Omicron variant XBB.1.5 of SARS-CoV-2. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is no longer authorized for use in the United States.\n\nPfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for use as follows:\n\nIndividuals 6 months through 4 years of age:\n\nUnvaccinated individuals: Three doses of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) are administered. The first two doses are administered three weeks apart. The third dose is administered at least 8 weeks after the second dose.\n\nIndividuals who have received one dose of any Pfizer BioNTech COVID-19 Vaccine, including Pfizer-BioNTech COVID-19 Vaccine, Bivalent: Two doses of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) are administered. The first dose of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is administered three weeks after receipt of the previous dose and the second dose is administered at least 8 weeks later.\n\nIndividuals who have received two to four doses of any Pfizer BioNTech COVID-19 Vaccine, including Pfizer-BioNTech COVID-19 Vaccine, Bivalent: A single dose of Pfizer-BioNTech COVID 19 Vaccine (2023-2024 Formula) is administered at least 8 weeks after receipt of the last previous dose.\n\nIndividuals 5 years through 11 years of age, regardless of vaccination status:\n\nA single dose of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula). If previously vaccinated with any COVID-19 vaccine, administer at least 2 months after receipt of the last previous dose of any COVID-19 vaccine.\n\nImmunocompromised individuals 6 months through 11 years of age::\n\nComplete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2023-2024 Formula).\n\nPfizer-BioNTech COVID-19 Fact Sheets and Materials\n\nPfizer-BioNTech Regulatory Information (Emergency Use Authorization)\n\nFederal Register Notices\n\nTranslations of the Fact Sheet for Recipients and Caregivers"
    }
}